Work

Survival outcomes of human epidermal growth factor receptor 2 (HER2)–amplified and HER2-mutated left-sided colorectal cancer (CRC) patients treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs).

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.3543

Authors: Yu Jen Alexander Jan, Kieran Sweeney, Andrew Elliott, Ronan Wenhan Hsieh, Chaoyuan Kuang, Parham Habibzadeh, Shafia Rahman, Rachna Shroff, Heinz-Josef Lenz, Sanjay Goel, Aatur D. Singhi, Vikram C. Gorantla, John C. Rhee, Janie Yue Zhang, Anwaar Saeed, Dennis Hsu

Institutions: University of Pittsburgh, University of Pittsburgh Medical Center, Caris Life Sciences (United States), Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University of Arizona, University of Southern California, USC Norris Comprehensive Cancer Center, Rutgers Cancer Institute

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162563715

Cites:

Cited by:

Related to: